Reports Q2 revenue $17.7M, two estimates $24.6M. "Six months ago, Enhanced was a privately held startup with a bold idea and a great deal of skepticism aimed at it," said Maximilian Martin, Chief Executive Officer of Enhanced. "Today, we are a globally recognized sports brand, the only organization to have successfully conducted a medically supervised enhanced sporting event in history. Simultaneously, we have built the foundation for a personalized performance medicine business, which we believe can help redefine the next decade of health and wellness, particularly as the regulatory tailwinds we expect to arrive in the peptide space continue to develop. We achieved each of these milestones in just the first six months of 2026 and we are just getting started."

7/30 08:00

Enhanced Group Expands Supplement Business to 33 Countries

Enhanced Group announced the international expansion of its direct-to-consumer supplement business, making its Stronger+ and Longer+ products available for customers in 33 countries beyond the United States. The expansion covers 27 European Union member states, the United Kingdom, Canada, Australia, Mexico, Japan and Colombia. "We've seen strong interest from customers well beyond the U.S. driven by the global visibility of the inaugural Enhanced Games," said Maximilian Martin, CEO of Enhanced. "I am proud of our team for working quickly to make new markets for our products available, which allows us to meet demand and hold our products to one global standard, no matter where an order originates."

7/27 08:00

Enhanced Group Commends FDA for Adding Peptides to 503A List

Enhanced Group commended the United States Food & Drug Administration's, FDA, Pharmacy Compounding Advisory Committee, PCAC, for its vote last week recommending that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to the FDA's Section 503A Bulk Drug Substances List. This recommendation is a "critical step" toward providing licensed U.S. compounding pharmacies a legal, regulated pathway to prepare these peptides for consumers, many of whom currently secure these substances via unregulated providers.

6/30 08:00

Enhanced Launches Thor Protocol to Support Physical Performance

Enhanced announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. Co-Created with Hafthor "Thor" Bjornsson, World's Strongest Man Champion and the most decorated strength athlete in the history of the sport, The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The company said, "Thor's Protocol includes three clinician-prescribed products, each personalized to the individual's lab results and health profile. Testosterone Injections: Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor's protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+: NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+'s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Low-Dose Tadalafil: Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual."

6/18 07:30

Enhanced Group Closes Initial Tranche of $50M Private Financing

Enhanced Group announced the closing of the initial tranche of its previously disclosed $50M private investment in public equity financing. The remaining tranches are expected to close following customary regulatory and stock exchange approvals. The financing is led by Apeiron Investment Group, the family office of Enhanced Co-Founder and Chairman Christian Angermayer, with participation from Co-Founder and CEO Maximilian Martin, with ticket sizes of $20M and $5M respectively, as well as leading global institutional investors. Following the inaugural Games, existing sponsors have expressed interest in renewing for 2027, while inbound demand from prospective sponsors continues to accelerate. The Company currently expects the sports business to achieve profitability in 2027.

查看更多事件

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。